» Articles » PMID: 18192235

The Anti-inflammatory and Anti-angiogenic Role of Mesenchymal Stem Cells in Corneal Wound Healing Following Chemical Injury

Overview
Journal Stem Cells
Date 2008 Jan 15
PMID 18192235
Citations 169
Authors
Affiliations
Soon will be listed here.
Abstract

To investigate the anti-inflammatory and anti-angiogenic effects of mesenchymal stem cells (MSC) in the chemically burned corneas, we mechanically removed the corneal epithelium of rats after 100% alcohol instillation. The rats were then randomized into four groups: fresh media, conditioned media derived from the MSC culture (MSC-CM), MSC applied topically to the damaged corneas for 2 hours immediately after the injury or MSC-CM applied either once or 3 times per day for 3 consecutive days. Corneal surface was evaluated every week. After 3 weeks, the corneas were stained with the hematoxylin-eosin, and the expression of interleukin (IL)-2, interferon (IFN)-gamma, IL-6, IL-10, transforming growth factor (TGF)-beta1, thrombospondin-1 (TSP-1), matrix metalloproteinase-2 (MMP-2), and vascular endothelial growth factor (VEGF) were analyzed. CD4+ cells were assessed in the corneas. We found that both MSC and three-time applied MSC-CM (1) reduced corneal inflammation and neovascularization, (2) decreased IL-2 and IFN-gamma, although increased IL-10 and TGF-beta1 as well as IL-6, (3) reduced the infiltration of CD4+ cells, and (4) upregulated the expression of TSP-1, although downregulated that of MMP-2. Interestingly, whereas three-time application of MSC-CM was partially effective, transplantation of MSC achieved a better outcome in suppressing corneal inflammation. The results of this study suggest that the anti-inflammatory and anti-angiogenic action of MSC in the chemically burned corneas might be mediated in part through paracrine pathways involving soluble factors such as IL-10, TGF-beta1, IL-6 and TSP-1.

Citing Articles

Oxygenated Exosome-Based Nanoeyedrop for Mitigating Hypoxia in Corneal Wound Healing: Impact on Healing Properties of Human Corneal Epithelial Cells.

Han X, Ju L, Sands M, Zhao Y, Irudayaraj J ACS Pharmacol Transl Sci. 2025; 8(2):602-612.

PMID: 39974628 PMC: 11833733. DOI: 10.1021/acsptsci.4c00724.


Biomedical Application of MSCs in Corneal Regeneration and Repair.

De Miguel M, Cadenas-Martin M, Stokking M, Martin-Gonzalez A Int J Mol Sci. 2025; 26(2).

PMID: 39859409 PMC: 11766311. DOI: 10.3390/ijms26020695.


Perspectives and Limitations of Mesenchymal Stem Cell-Based Therapy for Corneal Injuries and Retinal Diseases.

Hermankova B, Javorkova E, Palacka K, Holan V Cell Transplant. 2025; 34:9636897241312798.

PMID: 39856809 PMC: 11760125. DOI: 10.1177/09636897241312798.


Advances in the Diagnosis and Management of Limbal Stem Cell Deficiency.

Kittipibul T, Dalin C, Masoudi A, Zheng J, Deng S Cornea. 2024; 44(4):405-411.

PMID: 39729420 PMC: 11875906. DOI: 10.1097/ICO.0000000000003775.


Effect of Subconjunctival Injection of Canine Adipose-Derived Mesenchymal Stem Cells on Canine Spontaneous Corneal Epithelial Defects.

Kengkla P, Panyasing Y, Thayananuphat A, Tuntivanich N Animals (Basel). 2024; 14(22).

PMID: 39595323 PMC: 11591453. DOI: 10.3390/ani14223270.